Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation - Sportif II: A dose-guiding, tolerability, and safety study

Journal of the American College of Cardiology

Volumn 41, Issue 9, 2003, Pages 1445-1451

  Petersen, Palle ^a   Grind, Margaretha ^b   Adler, John ^c  

^a Rigshospitalet   (Denmark)

^b ASTRAZENECA   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; WARFARIN; XIMELAGATRAN;

ACCIDENT; ADULT; AGED; ARTICLE; BLOOD CLOTTING; CAPILLARY RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEMATURIA; HUMAN; INJURY; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; VERTIGO;

EID: 0038185371     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00255-9     Document Type: Article

References (20)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: the Framingham Study. Arch Intern Med 1987;147:1561-4.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
3. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001;119 Suppl:194S-206S.
4. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
5. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175-9.
6. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
7. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-55.
8. Stroke Prevention in Atrial Fibrillation study: final results. Circulation 1991;84:527-39.
9. Ezekowitz MD, Bridgers SL, James KE, et al., the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
10. Cowburn P, Cleland JG. SPAF-III results. Eur Heart J 1996;17:1129.
11. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
12. Fuster V, Rydén LE, Asinger RW, et al. The ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol 2001;38:1-70.
13. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41-6.
14. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.
15. Collin C, Wade DT, Davies S, Horne V. The Barthel ADL index: a reliability study. Int Disabil Stud 1988;10:61-3.
16. Grind M, Hamren B, Bååthe S, Wollbratt M, Eriksson UG. Pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation receiving long-term treatment: a population analysis by nonlinear mixed effect modeling. Clin Pharmacol Ther 2002;71:31.
17. Eriksson BI, Bergqvist D, Kälebo P, et al. A randomised, controlled study of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H 376/95), and its active form, melagatran, compared with dalteparin as thromboprophylaxis after total hip or total knee replacement: METHRO II. Lancet 2002;360:1441-7.
18. Heit JA, Colwell CW, Francis CW, et al., for the AstraZeneca Arthroplasty Study Group. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001;161:2215-21.
19. Mattsson C, Menschik-Lundin A, Wählander K, Lindahl TL. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thromb Haemost 2001;86:611-5.
20. Carlson MK, Gleason PP, Sen S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. Pharmacotherapy 2001;21:108-13.